This, together with its virtual absence in normal differentiated cells and embryonic expression pattern allows us to propose that RPSAP52 is an oncofetal pseudogene that enhances proliferative and survival programs across several tumor types and whose expression in cancer can have important clinical implications. This evidence concerns the gene RPSAP52 and cancer.